Rapid Visualization of Human Tumor Xenografts through Optical Imaging with a Near-Infrared Fluorescent Anti–Epidermal Growth Factor Receptor Nanobody
Open Access
- 1 January 2012
- journal article
- Published by SAGE Publications in Molecular Imaging
- Vol. 11 (1) , 33-46
Abstract
Given that overexpression of the epidermal growth factor receptor (EGFR) is found in many types of human epithelial cancers, noninvasive molecular imaging of this receptor is of great interest. A number of studies have employed monoclonal antibodies as probes; however, their characteristic long half-life in the bloodstream has encouraged the development of smaller probes. In this study, an anti-EGFR nanobody-based probe was developed and tested in comparison with cetuximab for application in optical molecular imaging. To this aim, the anti-EGFR nanobody 7D12 and cetuximab were conjugated to the near-infrared fluorophore IRDye800CW. 7D12-IR allowed the visualization of tumors as early as 30 minutes postinjection, whereas with cetuximab-IR, no signal above background was observed at the tumor site. Quantification of the IR-conjugated proteins in the tumors revealed ≈ 17% of injected dose per gram 2 hours after injection of 7D12-IR, which was significantly higher than the tumor uptake obtained 24 hours after injection of cetuximab-IR. This difference is associated with the superior penetration and distribution of 7D12-IR within the tumor. These results demonstrate that this anti-EGFR nanobody conjugated to the NIR fluorophore has excellent properties for rapid preclinical optical imaging, which holds promise for its future use as a complementary diagnostic tool in humans.Keywords
This publication has 50 references indexed in Scilit:
- Epidermal Growth Factor Receptor–Targeted Radioimmunotherapy of Human Head and Neck Cancer Xenografts Using 90Y-Labeled Fully Human Antibody PanitumumabMolecular Cancer Therapeutics, 2010
- Antibody Vectors for ImagingSeminars in Nuclear Medicine, 2010
- Strategies for Molecular Imaging of Epidermal Growth Factor Receptor Tyrosine Kinase in CancerJournal of Nuclear Medicine, 2009
- Disparity Between In Vivo EGFR Expression and 89Zr-Labeled Cetuximab Uptake Assessed with PETJournal of Nuclear Medicine, 2008
- Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine ModalitiesCurrent Pharmaceutical Design, 2008
- Cetuximab: Preclinical Evaluation of a Monoclonal Antibody Targeting EGFR for Radioimmunodiagnostic and Radioimmunotherapeutic ApplicationsCancer Biotherapy and Radiopharmaceuticals, 2008
- EGFR Antagonists in Cancer TreatmentNew England Journal of Medicine, 2008
- Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast CancerJNCI: Journal of the National Cancer Institute, 2004
- The EGFR family and its ligands in human cancerEuropean Journal of Cancer, 2001
- Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chainsProtein Engineering, Design and Selection, 1994